IL198829A0 - Gm-csf antagonist use in treating chronic inflammatory diseases - Google Patents

Gm-csf antagonist use in treating chronic inflammatory diseases

Info

Publication number: IL198829A0
Authority: IL; Israel
Prior art keywords: inflammatory diseases; chronic inflammatory; treating chronic; csf antagonist; antagonist use
Prior art date: 2006-11-21

Application number

IL198829A

Original Assignee

Kalobios Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-21

Filing date

2009-05-19

Publication date

2010-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL198829(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-19 Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc

2010-02-17 Publication of IL198829A0 publication Critical patent/IL198829A0/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)

IL198829A 2006-11-21 2009-05-19 Gm-csf antagonist use in treating chronic inflammatory diseases IL198829A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86078006P	2006-11-21	2006-11-21
US90274207P	2007-02-21	2007-02-21
PCT/US2007/085402 WO2008064321A2 (en)	2006-11-21	2007-11-21	Methods of treating chronic inflammatory diseases using a gm-csf antagonist

Publications (1)

Publication Number	Publication Date
IL198829A0 true IL198829A0 (en)	2010-02-17

Family

ID=39386167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL198829A IL198829A0 (en)	2006-11-21	2009-05-19	Gm-csf antagonist use in treating chronic inflammatory diseases

Country Status (15)

Country	Link
US (2)	US20080206241A1 (en)
EP (2)	EP2402013A1 (en)
JP (1)	JP5410293B2 (en)
KR (1)	KR101517251B1 (en)
CN (2)	CN101605547A (en)
AU (1)	AU2007323541B2 (en)
BR (1)	BRPI0719109A2 (en)
CA (1)	CA2670288C (en)
EA (1)	EA200900709A1 (en)
ES (1)	ES2432173T3 (en)
IL (1)	IL198829A0 (en)
MX (1)	MX2009005398A (en)
NZ (1)	NZ598345A (en)
SG (1)	SG176503A1 (en)
WO (1)	WO2008064321A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101605547A (en)	2006-11-21	2009-12-16	卡罗拜奥斯制药公司	Methods of treating chronic inflammatory diseases using GM-CSF antagonists
EP2222846B1 (en) *	2007-08-10	2017-05-03	Protelix, Inc.	Universal fibronectin type iii binding-domain libraries
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
US8680019B2 (en) *	2007-08-10	2014-03-25	Protelica, Inc.	Universal fibronectin Type III binding-domain libraries
TW200918553A (en) *	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
PT2215119E (en)	2007-11-13	2013-02-11	Boehringer Ingelheim Int	Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
ATE555131T1 (en) *	2008-01-15	2012-05-15	Kalobios Pharmaceuticals Inc	METHOD FOR TREATING BONE DEPOSITIVE DISEASES USING A GM-CSF ANTAGONIST
US8075885B2 (en) *	2008-04-07	2011-12-13	Kalobios Pharmaceuticals, Inc.	Methods of treating heart failure using an anti-GM-CSF antibody
EP2280732B1 (en)	2008-04-28	2018-10-17	Humanigen, Inc.	Antibodies to granulocyte-macrophage colony-stimulating factor
PL2376121T5 (en) *	2008-12-22	2021-09-27	The University Of Melbourne	Osteoarthritis treatment
CA2747206C (en)	2008-12-22	2018-04-24	The University Of Melbourne	Pain treatment
AU2015224416B2 (en) *	2008-12-22	2017-04-20	The University Of Melbourne	Osteoarthritis treatment
WO2010093814A1 (en) *	2009-02-11	2010-08-19	Kalobios Pharmaceuticals, Inc.	Methods of treating dementia using a gm-csf antagonist
CN102459340A (en) *	2009-04-23	2012-05-16	特罗科隆科学有限公司	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AU2010244525B2 (en) *	2009-05-05	2013-03-28	Morphosys Ag	Treatment for multiple sclerosis
JP2014520784A (en) *	2011-07-06	2014-08-25	モルフォシス・アー・ゲー	Therapeutic combination of anti-CD20 antibody and anti-GM-CSF antibody and use thereof
KR20210021153A (en) *	2012-09-20	2021-02-24	모르포시스 아게	Treatment for rheumatoid arthritis
MY175388A (en) *	2012-09-20	2020-06-23	Morphosys Ag	Treatment for rheumatoid arthritis
AR093297A1 (en) *	2012-10-31	2015-05-27	Amgen Res Munich Gmbh	LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
WO2015028657A1 (en) *	2013-08-30	2015-03-05	Takeda Gmbh	Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP6360696B2 (en) *	2014-03-18	2018-07-18	日本光電工業株式会社	Blood test apparatus and blood test method
CN106456761A (en) *	2014-05-19	2017-02-22	免疫医疗有限公司	Treatment for rheumatoid arthritis
US20180236098A1 (en) *	2016-08-12	2018-08-23	L.E.A.F. Holdings Group Llc	Alpha and gamma-d polyglutamated antifolates and uses thereof
KR101953706B1 (en)	2016-09-19	2019-03-05	아이-맵	Anti-GM-CSF antibody and its use
EP3691663A4 (en) *	2017-10-02	2021-08-18	Humanigen, Inc.	METHOD OF TREATING IMMUNOTHERAPY ASSOCIATED TOXICITY USING GM-CSF ANTAGONIST
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US20220040229A1 (en) *	2018-10-31	2022-02-10	Humanigen, Inc.	Materials and methods for treating cancer
CN115605508A (en) *	2020-03-08	2023-01-13	赫曼尼根公司（Us）	Methods for treating coronavirus infection and resulting inflammation-induced lung injury
CA3198765A1 (en) *	2020-12-04	2022-06-09	Catherine Mary Owczarek	Methods for treating inflammatory skin conditions
US20240317846A1 (en) *	2021-03-08	2024-09-26	Humanigen, Inc.	Methods for treating coronavirus infection and resulting inflammation-induced lung injury
WO2023138499A1 (en) *	2022-01-20	2023-07-27	舒泰神（北京）生物制药股份有限公司	Antibody preparation for specifically recognizing granulocyte-macrophage colony-stimulating factor receptor and use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPS6412935A (en)	1987-07-02	1989-01-17	Mitsubishi Electric Corp	Constant-speed travel device for vehicle
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
NZ234479A (en) *	1989-07-14	1992-03-26	Schering Corp	Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
WO1994009149A1 (en)	1990-08-10	1994-04-28	Amrad Corporation Limited	Monoclonal antibody
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (en)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	Method for producing xenogeneic immunoglobulin and transgenic mouse
US6258562B1 (en)	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US5770380A (en)	1996-09-13	1998-06-23	University Of Pittsburgh	Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
CA2342967A1 (en)	1998-12-08	2000-06-15	Biovation Limited	Modifying protein immunogenicity
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7108852B2 (en) *	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) *	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
JP2006500905A (en)	2002-02-13	2006-01-12	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	Humanized GM-CSF antibody
GB0224082D0 (en) *	2002-10-16	2002-11-27	Celltech R&D Ltd	Biological products
EP2526960A1 (en) *	2003-03-12	2012-11-28	Genentech, Inc.	Use of BV8 and/or EG-VEGF to promote hematopoiesis
CA2533598C (en) *	2003-07-23	2012-09-11	Synta Pharmaceuticals, Corp.	Method for modulating calcium ion-release-activated calcium ion channels
JP4782700B2 (en)	2004-01-20	2011-09-28	カロバイオスファーマシューティカルズインコーポレイティッド	Transfer of antibody specificity using minimally required binding determinants
RU2396982C2 (en) *	2004-07-16	2010-08-20	Киорин Фармасьютикал Ко., Лтд.	Effective method of using drugs and method for prevention of by-effects intensity
DK2343380T3 (en)	2004-11-16	2019-09-09	Humanigen Inc	IMMUNOGLOBULIN VARIABLE REGION CARTRIDGE REPLACEMENT
PL3620171T3 (en)	2005-05-18	2022-08-08	Morphosys Ag	ANTI-GM-CSF ANTIBODIES AND THEIR APPLICATIONS
US20080305079A1 (en) *	2006-01-06	2008-12-11	Mount Sinai School Of Medicine Of New York University	Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
HRP20170024T1 (en) *	2006-02-08	2017-03-10	Morphotek, Inc.	GM-CSF ANTIGENS PEPTIDES AND ANTI-ANTIBODIES AGAINST GM-CSF
PT2423229E (en)	2006-03-27	2013-08-22	Medimmune Ltd	Binding member for gm-csf receptor
DE102006033837A1 (en) *	2006-07-21	2008-01-31	Medac Gesellschaft für klinische Spezialpräparate m.b.H	Concentrated methotrexate solutions
CN101605547A (en)	2006-11-21	2009-12-16	卡罗拜奥斯制药公司	Methods of treating chronic inflammatory diseases using GM-CSF antagonists

2007
- 2007-11-21 CN CNA2007800495322A patent/CN101605547A/en active Pending
- 2007-11-21 CA CA2670288A patent/CA2670288C/en not_active Expired - Fee Related
- 2007-11-21 BR BRPI0719109-0A2A patent/BRPI0719109A2/en not_active IP Right Cessation
- 2007-11-21 MX MX2009005398A patent/MX2009005398A/en active IP Right Grant
- 2007-11-21 EA EA200900709A patent/EA200900709A1/en unknown
- 2007-11-21 AU AU2007323541A patent/AU2007323541B2/en not_active Ceased
- 2007-11-21 US US11/944,162 patent/US20080206241A1/en not_active Abandoned
- 2007-11-21 EP EP11182971A patent/EP2402013A1/en not_active Withdrawn
- 2007-11-21 EP EP07868831.4A patent/EP2101780B1/en not_active Revoked
- 2007-11-21 ES ES07868831T patent/ES2432173T3/en active Active
- 2007-11-21 WO PCT/US2007/085402 patent/WO2008064321A2/en not_active Ceased
- 2007-11-21 CN CN201510674256.5A patent/CN105435223A/en active Pending
- 2007-11-21 KR KR1020097012906A patent/KR101517251B1/en not_active Expired - Fee Related
- 2007-11-21 SG SG2011085834A patent/SG176503A1/en unknown
- 2007-11-21 NZ NZ598345A patent/NZ598345A/en not_active IP Right Cessation
- 2007-11-21 JP JP2009538506A patent/JP5410293B2/en not_active Expired - Fee Related
2009
- 2009-05-19 IL IL198829A patent/IL198829A0/en unknown
2015
- 2015-05-14 US US14/712,627 patent/US20150246121A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BRPI0719109A2 (en)	2013-12-10
KR101517251B1 (en)	2015-05-07
JP2010510323A (en)	2010-04-02
AU2007323541B2 (en)	2012-01-19
SG176503A1 (en)	2011-12-29
MX2009005398A (en)	2009-08-20
KR20090110827A (en)	2009-10-22
NZ598345A (en)	2013-09-27
CA2670288A1 (en)	2008-05-29
ES2432173T3 (en)	2013-12-02
US20080206241A1 (en)	2008-08-28
CN101605547A (en)	2009-12-16
WO2008064321A2 (en)	2008-05-29
EP2101780A2 (en)	2009-09-23
CA2670288C (en)	2015-10-27
EP2101780B1 (en)	2013-10-09
AU2007323541A1 (en)	2008-05-29
CN105435223A (en)	2016-03-30
WO2008064321A3 (en)	2008-10-02
JP5410293B2 (en)	2014-02-05
EA200900709A1 (en)	2009-12-30
EP2402013A1 (en)	2012-01-04
US20150246121A1 (en)	2015-09-03

Publication	Publication Date	Title
IL198829A0 (en)	2010-02-17	Gm-csf antagonist use in treating chronic inflammatory diseases
EP2069784A4 (en)	2009-11-18	Il-33 in inflammatory disease
EP2035005A4 (en)	2011-07-06	Therapy using cytokine inhibitors
GB2435046B (en)	2010-04-07	Temporary plugs for use in wellbores
IL194739A0 (en)	2009-08-03	Dihydrothienopyrimidine for treating inflammatory disorders
EP2214669A4 (en)	2011-11-09	Cytokine inhibitors
PT2050749T (en)	2018-01-02	Pyrimidine derivative as pi3k inhibitor and use thereof
IL193230A (en)	2015-10-29	Use of benzoxaborole derivatives in the manufacture of medicaments for treating inflammatory diseases
ZA200900305B (en)	2009-12-30	Dressing
IL201367A0 (en)	2010-05-31	2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
PL2101731T3 (en)	2018-07-31	Endoxifen for use in the treatment of cancer
GB0610553D0 (en)	2006-07-05	Dressing
IL193116A0 (en)	2009-02-11	Antagonists of il-18r in diseases
IL199214A0 (en)	2010-03-28	New combination for use in the treatment of inflammatory disorders
IL195817A0 (en)	2009-09-01	Use of 2-benzoyl-imidazopyridines in therapeutics
GB2450580B (en)	2010-04-14	Poly-TLR antagonist
EP2013274A4 (en)	2010-06-02	Combination of additives for use in preparation of termoplastics
GB0623196D0 (en)	2006-12-27	Dressing
IL197637A0 (en)	2011-08-01	4-1 bb ligand in inflammatory diseases
ZA200904249B (en)	2010-08-25	New combination for use in the treatment of inflammatory disorders
TWI339624B (en)	2011-04-01	Templet used in designing
GB0605454D0 (en)	2006-04-26	Cue factor
GB0614970D0 (en)	2006-09-06	Compounds For Use In Therapy
GB0603585D0 (en)	2006-04-05	Pteridines for use in the manufacture of a medicament for treating inflammatory bowel diseases
HK1133081A (en)	2010-03-12	Il-33 in inflammatory disease